<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CARBENICILLIN INDANYL SODIUM</span><br/>(kar-ben-i-sill'in)<br/><span class="topboxtradename">Geocillin, </span><span class="topboxtradename">Geopen Oral <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">antipseudomonal penicillin</span><br/><b>Prototype: </b>Piperacillin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>382 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Broad-spectrum, semisynthetic penicillin and acid stable ester of carbenicillin prepared for oral use. Rapidly hydrolyzed
         to carbenicillin in body.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Like carbenicillin disodium, it is bactericidal and penicillinase sensitive and has similar antimicrobial activity but achieves
         lower blood concentrations than parent compound. Reduces the discomfort of prostatitis and effective in reducing symptoms
         of urinary tract infections.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Mainly in the treatment of prostatitis and acute and chronic infections of upper and lower urinary tract caused by susceptible
         strains of <i>Escherichia coli, Enterobacter, Enterococcus, Proteus,</i> and <i>Pseudomonas species</i>.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to penicillins; pregnancy (category B). Safe use in children not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of or suspected atopy or allergies; history of allergy to cephalosporins; lactation; impaired renal and hepatic function;
         patients on sodium restriction.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urinary Tract Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 382764 mg q6h for 10 d, continue for 24 wk for prostatitis<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with a full glass (240 mL) of water on an empty stomach (either 1 h before or 2 h after meals) to attain maximum therapeutic
            drug levels in urine. Consult physician.
         </li>
<li>Protect tablets from moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (Rash, fever, urticaria, eosinophilia, pruritus, <span class="speceff-life">anaphylaxis</span>), superinfections, especially of vagina. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> vomiting, heartburn; <span class="speceff-common">diarrhea,</span> abdominal cramps, flatulence, unpleasant aftertaste, dry mouth. <span class="typehead">Hematologic:</span> Neutropenia, leukopenia, thrombocytopenia, <span class="speceff-life">hemolytic anemia</span>, increased AST. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely absorbed from GI tract. <span class="typehead">Peak:</span> 0.51 h. <span class="typehead">Distribution:</span> Very low systemic concentrations; crosses placenta; distributed into breast milk. <span class="typehead"> Elimination:</span> 8099% excreted unchanged in urine within 24 h. <span class="typehead">Half-Life:</span> 67 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform culture and sensitivity tests prior to and at regular intervals throughout therapy. Therapy may be initiated
            pending test results. Evaluate renal, hepatic, and hematopoietic systems at regular intervals during prolonged therapy. Patients
            with creatinine clearance of less than 10 mL/min (normal: 105130 mL/min) will not attain therapeutic urine levels.
         </li>
<li>Inquire carefully concerning patient's previous exposure and sensitivity to penicillin and cephalosporins and other allergic
            reactions of any kind before treatment is initiated.
         </li>
<li>Note that drug-induced nausea, unpleasant aftertaste and smell, dry mouth, and furry tongue may be so objectionable as to
            necessitate drug withdrawal. Report to physician if symptoms persist.
         </li>
<li>Monitor I&amp;O rates and pattern: Check with physician regarding optimum daily fluid intake. Report any change in quality or
            quantity of urine or in I&amp;O ratio.
         </li>
<li>Observe patient for signs of electrolyte imbalance. Each 1 g of drug contains approximately 1 mEq of sodium.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take this medication with a full glass of water on an empty stomach.</li>
<li>Take medication around the clock, do not miss any doses, and continue taking medication until it is all gone unless otherwise
            directed by physician.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>